Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 16 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Oct 2023.
- 15 Oct 2020 Status changed from not yet recruiting to recruiting.